SORCS2-derived macrocyclic peptides

SORCS2-derived macrocyclic peptides has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 9, 2026: “Peptide improved movement in mouse models of brain disease”.

Intervention

1 paper studies it1 findingUpdated

1 new paper in 30 daysSee all 1 papers on SORCS2-derived macrocyclic peptides

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: CHDI Foundation and 5 more
  • 1 of 1 finding with company ties
  • Animals1

What did studies of SORCS2-derived macrocyclic peptides find?

1

Studies of SORCS2-derived macrocyclic peptides measured one outcome, CREB and AMPK signaling.

CREB and AMPK signaling

upin animals1

1 study
  1. SORCS2-derived macrocyclic peptides activate CREB and AMPK signaling.

    “SorCS2-peptides enhance both neurotrophic support and boost metabolism by activating both CREB and AMPK potentially via a CAMKK2-dependent mechanism.”

    Animals

    Peptide improved movement in mouse models of brain disease

    Acta neuropathologica communications

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months
Acta Neuropathologica Communications

Peptide improved movement in mouse models of brain disease

Daily injections from 3 to 12 months of age improved movement and behavior in male and female mice modeling Huntington’s disease.Daily injections from 3 to 12 months of age improved movement and behavior in male and female mice modeling Huntington’s disease.

Mouse studyInterventions